Use of MDCK cells for production of live attenuated influenza vaccine
Use of MDCK cells for production of live attenuated influenza vaccine
复制标题
DOI：
10.1016/j.vaccine.2009.06.024
复制
发表时间：
2009-01-01
期刊：
影响因子：
5.5
通讯作者：
Kemble, George
中科院分区：
文献类型：
--
作者：
Liu, Jonathan;Shi, Xiao;Kemble, George
为了开发基于细胞的流感减毒活疫苗（LAIV）生产工艺，通过比较LAIV毒株感染后病毒的滴度来评价几种不同的细胞系。虽然已经报道了几种细胞系支持流感病毒复制，但尚未系统地检查LAIV毒株的复制程度和支持复制的能力。除Vero、MRC-5、WI-38和FRhL细胞外，还评价了MDCK细胞（被认为是流感疫苗生产的潜在底物）。MRC-5、WI-38和FRhL细胞产生低至中等滴度的病毒，滴度等于或低于5.0 log（10）TCID（50）/mL Vero和MDCK细胞都可以支持某些毒株更高水平的病毒复制，然而，当在血清存在下生长时，Vero细胞仅产生高滴度。MDCK细胞在含血清和无血清培养基中均支持多种不同LAIV亚型的高水平疫苗病毒生产。这些结果表明，基于MDCK细胞的生产可以用作目前使用的基于蛋的LAIV生产系统的替代生产平台。(C)2009爱思唯尔有限公司保留所有权利。
To develop a cell-based live attenuated influenza vaccine (LAIV) manufacturing process, several different cell lines were evaluated by comparing the titer of viruses after infection with LAIV strains. While several cell lines have been reported to support influenza virus replication, the degree of replication and the ability to support replication of LAIV strains have not been systematically examined. MDCK cells, which have been considered as potential substrates for influenza vaccine production were evaluated in addition to Vero, MRC-5, WI-38 and FRhL cells. MRC-5, WI-38 and FRhL cells produced low to moderate titers of virus with titers equal or below 5.0 log(10) TCID(50)/mL Both Vero and MDCK cells could support a higher level of virus replication for certain strains, however, Vero cells only produced high titers when grown in the presence of serum. MDCK cells supported high levels of vaccine virus production for multiple different LAIV subtypes in both serum containing and serum-free media. These results suggest that MDCK cell-based production can be used as an alternative production platform to the currently used egg-based LAIV production system. (C) 2009 Elsevier Ltd. All rights reserved.